EDP 323
Alternative Names: EDP-323Latest Information Update: 15 Apr 2025
At a glance
- Originator Enanta Pharmaceuticals
- Class Antivirals; Small molecules
- Mechanism of Action RNA-dependent RNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Respiratory syncytial virus infections
Most Recent Events
- 08 Apr 2025 Enanta Pharmaceuticals initiates a phase I drug-drug interaction trial in Respiratory syncytial virus infections (In volunteers) in USA (PO) (NCT06917508)
- 10 Feb 2025 EDP 323 is available for licensing as of 10 Feb 2025. http://enanta.com/pipeline/pipeline-overview/
- 27 Jan 2025 Enanta Pharmaceuticals initiates a phase I drug-drug interaction trial in Respiratory syncytial virus infections (In volunteers) in USA (PO) (NCT06847464)